Literature DB >> 6286011

Analysis of T lymphocytes after bone marrow transplantation using monoclonal antibodies.

R Fox, R McMillan, W Spruce, P Tani, D Mason.   

Abstract

Using monoclonal antibodies to cell surface antigens and fluorescent cell sorter analysis, we studied peripheral blood lymphocyte subsets after bone marrow transplantation (BMT). In 13 patients studied 3 mo or more after BMT, the ratio of T-cell subsets defined by antibodies OKT4 and OKT8 was reversed (OKT4/OK%8 = 0.7 +/- 0.3) in comparison to normal volunteers or bone marrow donors (ratio OKT4/OKT8 = 1.7 +/- 0.4) (p less than 0.001). This reversed ratio persisted for up to 3 yr after BMT. In contrast to a previous report, presence of an abnormal ratio of T-cell subsets did not correlate with clinically significant graft-versus-host disease (GVHD). In agreement with a previous study, (26% +/- 8%; less than 4% in normals (p less than 0.001) and antibody OKT10 reactive cells (39% +/- 20% versus 10% +/- 4%) (p less than 0.01), suggesting in vivo activation. However, their PBL did not react with antibody B3/25 (antitransferrin receptor), a marker found on normal PBL after in vitro activation by mitogens (BMT patients less than 5%; normal PBL T cells plus PHA 45% +/- 11%). These results demonstrate that BMT patients have: (A) an abnormal ratio of T-cell subsets in the presence or absence of clinically significant GVDH disease so that these measurements were not useful in monitoring patients; (B) an increased number of T cells with cell surface phenotype (OKT8+, Ia+, OKT10+, B3/25-) that is distinct from normals but similar to patients with infectious mononucleosis or acquired hypogammaglobulinemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286011

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Functional analysis of CD8 lymphocytes in long-term surviving patients after bone marrow transplantation.

Authors:  M Divine; J P Lecouedic; M F Gourdin; N Oudhriri; M Zohair; T Henni; F Beaujan; J P Vernant; F Reyes; J P Farcet
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

2.  Bone marrow transplantation in the rat. III. Structure of the liver inflammatory lesion in acute graft-versus-host disease.

Authors:  D Leszczynski; R Renkonen; P Häyry
Journal:  Am J Pathol       Date:  1985-08       Impact factor: 4.307

Review 3.  Immune reconstitution following bone marrow transplantation.

Authors:  U N Verma; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

Review 4.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

5.  Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow.

Authors:  A Parreira; J Smith; J M Hows; S A Smithers; J Apperley; Y Rombos; J M Goldman; E C Gordon-Smith; D Catovsky
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

Review 6.  Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sarah M Tete; Marc Bijl; Surinder S Sahota; Nicolaas A Bos
Journal:  Front Immunol       Date:  2014-06-03       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.